The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sultanbaev A.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University;
Republican Medical Genetic Center;
Institute of Immunology and Physiology

Tuzankina I.A.

Institute of Immunology and Physiology;
Regional Children Hospital

Nasretdinov A.F.

Republican Clinical Oncology Dispensary

Menshikov K.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University;
Republican Medical Genetic Center

Askarov V.E.

Republican Clinical Oncology Dispensary

Musin Sh.I.

Republican Clinical Oncology Dispensary

Sultanbaeva N.I.

Republican Clinical Oncology Dispensary

Izmailov A.A.

Republican Clinical Oncology Dispensary

Menshikova I.A.

Bashkir State Medical University

Kudlay D.A.

Bashkir State Medical University;
Sechenov First Moscow State Medical University (Sechenov University);
Institute of Immunology

Results of the use of immune checkpoint inhibitors in the treatment of small cell lung cancer in real-life clinical practice: results of a single-center observational study

Authors:

Sultanbaev A.V., Tuzankina I.A., Nasretdinov A.F., Menshikov K.V., Askarov V.E., Musin Sh.I., Sultanbaeva N.I., Izmailov A.A., Menshikova I.A., Kudlay D.A.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2025;14(4): 46‑53

DOI: 10.17116/onkolog20251404146

Read: 720 times

Buy for 300₽
Contact the author
Table of contents

RESULTS OF THE USE OF IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF SMALL CELL LUNG CANCER IN REAL-LIFE CLINICAL PRACTICE: RESULTS OF A SINGLE-CENTER OBSERVATIONAL STUDY
RESULTS OF THE USE OF IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF SMALL CELL LUNG CANCER IN REAL-LIFE CLINICAL PRACTICE: RESULTS OF A SINGLE-CENTER OBSERVATIONAL STUDY

To cite this article:

Sultanbaev AV, Tuzankina IA, Nasretdinov AF, et al. . Results of the use of immune checkpoint inhibitors in the treatment of small cell lung cancer in real-life clinical practice: results of a single-center observational study. P.A. Herzen Journal of Oncology. 2025;14(4):46‑53. (In Russ.)
https://doi.org/10.17116/onkolog20251404146

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Effi­cacy of chemoimmunotargeted therapy in patients with adva­nced non-small cell lung cancer in real clinical practice. P.A. Herzen Journal of Onco­logy. 2025;(3):63-70
The effe­ctiveness of combined chemotherapy and immu­notherapy, and the search for personalized approaches to treating adva­nced non-small cell lung cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):37-45
Preoperative indi­ces of systemic inflammatory response as predictors of the presence of regional meta­stases in cervical cancer. (A systematic review and meta-analysis). P.A. Herzen Journal of Onco­logy. 2025;(6):94-102
Surgical treatment of intracerebral meta­stases of Ewing sarcoma in children. Case report and review. Burdenko's Journal of Neurosurgery. 2025;(2):92-96
Levels of T-cell rece­ptor exci­sion rings and B-cell κ-deletion element in healthy indi­viduals in different age groups. Labo­ratory Service. 2025;(3):33-39
TRPS1 as a novel immu­nohistochemical marker in breast cancer diagnosis. Russian Journal of Archive of Pathology. 2026;(1):80-87
Abstract:

Small cell lung cancer (SCLC) is an aggressive tumor with early metastasis and a low 5-year survival rate (6.4%). Despite the use of PD-L1 inhibitors (atezolizumab, durvalumab) in combination with chemotherapy, outcomes remain unsatisfactory due to resistance and patient heterogeneity.

OBJECTIVE

To evaluate the effectiveness of immunochemotherapy (atezolizumab+carboplatin/etoposide) in real-world clinical practice in patients with metastatic SCLC.

MATERIAL AND METHODS

Data from 98 patients (87 men, 11 women, median age 62 years) over 50 months (2020—2024) were analyzed. Treatment regimen: carboplatin (AUC5), etoposide (100 mg/m²), and atezolizumab (1200 mg) every 3 weeks (4 cycles), followed by maintenance therapy. Progression-free survival (PFS), overall survival (OS), and the impact of metastases/comorbidities were assessed.

RESULTS

Median PFS was 6 months, OS was 12 months. Partial response was observed in 60.2%, stable disease in 23.5%, disease progression in 13.3%, and complete response in 3.1%. Metastases in the liver, bones, peritoneum, and kidneys significantly reduced PFS and OS (p< 0.05). Comorbidities had no significant impact.

CONCLUSION

The combination of atezolizumab with chemotherapy demonstrates efficacy comparable to clinical trial data, but outcomes depend on metastasis location. Metastatic involvement of the liver, bones, and peritoneum is associated with a worse prognosis, highlighting the need for personalized treatment approaches.

Keywords:

atezolizumab
TCR
immunity
small cell lung cancer
metastases

Authors:

Sultanbaev A.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University;
Republican Medical Genetic Center;
Institute of Immunology and Physiology

Tuzankina I.A.

Institute of Immunology and Physiology;
Regional Children Hospital

Nasretdinov A.F.

Republican Clinical Oncology Dispensary

Menshikov K.V.

Republican Clinical Oncology Dispensary;
Bashkir State Medical University;
Republican Medical Genetic Center

Askarov V.E.

Republican Clinical Oncology Dispensary

Musin Sh.I.

Republican Clinical Oncology Dispensary

Sultanbaeva N.I.

Republican Clinical Oncology Dispensary

Izmailov A.A.

Republican Clinical Oncology Dispensary

Menshikova I.A.

Bashkir State Medical University

Kudlay D.A.

Bashkir State Medical University;
Sechenov First Moscow State Medical University (Sechenov University);
Institute of Immunology

Received:

10.04.2025

Accepted:

17.06.2025

Close metadata

References:

  1. Menshikov KV, Sultanbaev AV, Musin ShI, Menshikova IA, Nasretdinov AF, Sultanbaeva NI. Treatment of advanced small cell lung cancer. Clinical case and literature review. Journal of Modern Oncology. 2021;23(1):112-115. (In Russ.). https://doi.org/10.26442/18151434.2021.1.200726
  2. Lee JH, Saxena A, Giaccone G. Advancements in small cell lung cancer. Semin Cancer Biol. 2023;123-128.  https://doi.org/10.1016/j.semcancer.2023.05.008
  3. Petty WJ, Paz-Ares L. Emerging Strategies for the Treatment of Small Cell Lung Cancer: A Review. JAMA Oncol.. 2022;89.  https://doi.org/10.1001/jamaoncol.2022.5631
  4. Tariq S, Kim SY, Novaes JMO, Cheng H. Management of Small Cell Lung Cancer. Lung. 2021;142.  https://doi.org/10.1007/s00408-021-00486-y
  5. Alongi F, Arcangeli S, De Bari B, Giaj-Levra N, Fiorentino A, Mazzola R, Trovo M. Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. Crit Rev Oncol Hematol. 2017;112:67-76.  https://doi.org/10.1016/j.critrevonc.2017.02.010
  6. Elshoeibi AM, Elsayed B, Kaleem MZ, Elhadary MR, Abu-Haweeleh MN, Haithm Y, Krzyslak H, Vranic S, Pedersen S. Proteomic Profiling of Small-Cell Lung Cancer: A Systematic Review. Cancers. 2023;65.  https://doi.org/10.3390/cancers15205005
  7. Johal S, Hettle R, Carroll J, Maguire P, Wynne T. Real-world treatment patterns and outcomes in small-cell lung cancer: a systematic literature review. J Thorac Dis. 2021;133.  https://doi.org/10.21037/jtd-20-3034
  8. Leonetti A, Minari R, Mazzaschi G, Gnetti L, La Monica S, Alfieri R, Campanini N, Verzè M, Olivani A, Ventura L, Tiseo M. Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review. Front Oncol. 2021;177.  https://doi.org/10.3389/fonc.2021.642190
  9. Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D’Amico TA, D’Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, et al. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(12):1441-1464. https://doi.org/10.6004/jnccn.2021.0058
  10. Li Y, Li C, Qi X, Yu L, Lin L. Management of small cell lung cancer complicated with paraneoplastic Cushing’s syndrome: a systematic literature review. Front Endocrinol. 2023;88.  https://doi.org/10.3389/fendo.2023.1177125
  11. Wang HY, Wang X, Jiang S, Zhu J, Liu J, Zhou C, Zhu Y, Han Y. Personalized treatment of extensive stage small cell lung cancer: A case report and literature review. Front Oncol. 2022;12:98.  https://doi.org/10.3389/fonc.2022.956372
  12. Digiacomo N, De Pas T, Rossi G, Bossi P, Stucchi E, Conforti F, Cocorocchio E, Laszlo D, Pala L, Zattarin E, Catania C. Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review. Curr Oncol. 2023;140.  https://doi.org/10.3390/curroncol30030265
  13. Bylsma LC, Pundole X, Ju CH, Hooda N, Movva N, Elkhouly E, Bebb G, Fryzek J, Martinez P, Balasubramanian A, Dingemans AMC. Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer. Target Oncol. 2023;47.  https://doi.org/10.1007/s11523-023-01008-x
  14. Imakita T, Fujita K, Kanai O, Okamura M, Hashimoto M, Nakatani K, Sawai S, Mio T. Small cell transformation of non-small cell lung cancer under immunotherapy: Case series and literature review. Thorac Cancer. 2021;22(12):3062-3067. https://doi.org/10.1111/1759-7714.14180
  15. Wu R, Li C, Wang Z, Fan H, Song Y, Liu H. A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia. Transl Lung Cancer Res. 2020;;9(6):2469-2478. https://doi.org/10.21037/tlcr-20-1147
  16. Sultanbaev AV, Tuzankina IA, Nasretdinov AF, Sultanbaeva NI, Musin ShI, Menshikov KV, Sultanbaev MV, Satyshev OV, Izmailov AA, Kudlay DA, Imyanitov EN. Mechanisms of formation of specific antitumor immunity and resistance to immune checkpoint inhibitors. Voprosy Onkologii=Problems in Oncology. 2024;70(3):433-439. (In Russ.). https://doi.org/10.37469/0507-3758-2024-70-3-433-439
  17. Sultanbaev AV, Musin ShI, Menshikov KV, Izmailov AA, Nasretdinov AF, Sultanbaeva NI, Menshikova IA, Tsimafeyeu IV, Lipatov DO, Sultanbaev MV, Lipatov ON, Kudlay DA. The role of chromosomal V(D)J recombinations of lymphocytes in the formation of antitumor immunity and the effectiveness of immunotherapy. Molecular Medicine. 2023;21(4):11-19. (In Russ.). https://doi.org/10.29296/24999490-2023-04-02
  18. Shepherd R, Cheung AS, Pang K, Saffery R, Novakovic B. Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics. Front Immunol. 2021;11:604000. https://doi.org/10.3389/fimmu.2020.604000
  19. Nayak RK, Aiello M, Maldonado LM, Clark TY, Buchwald ZS, Chang A. Impact of race, ethnicity, and social determinants on outcomes following immune checkpoint therapy. J Immunother Cancer. 2024;12(10):e010116. https://doi.org/10.1136/jitc-2024-010116
  20. Wang Z, Aguilar EG, Luna JI, Dunai C, Khuat LT, Le CT, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, Grossenbacher SK, Withers SS, et al, Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade. Nat Med. 2019;25(1):141-151.  https://doi.org/10.1038/s41591-018-0221-5
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.